File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Diabetes gene therapy: potential and challenges.

TitleDiabetes gene therapy: potential and challenges.
Authors
Issue Date2003
PublisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cgt/index.htm
Citation
Current Gene Therapy, 2003, v. 3 n. 1, p. 65-82 How to Cite?
AbstractGene therapy, developing rapidly as a result of advances in molecular biology and the Human Genome Project, is now highlighted as a most hopeful technology of the 21st century. The major goal of gene therapy in diabetes mellitus (DM) is to maintain euglycemia in face of wide variations in dietary intake. Although some obstacles remain to be overcome, the risk-benefit ratio of gene therapy in DM is better than that of lifelong injections of insulin, and islet transplantation, which faces the problems of donor shortage and rejection. This review focuses on the recent advances in gene therapy of insulin-requiring diabetes, with particular emphasis on 1. the gene delivery systems by viral vectors, since most gene therapy approaches for DM involve the use of viral vectors, paying special attention to current efforts to overcome the disadvantages of adenovirus, adenovirus-associated virus and retrovirus vectors and targeting gene delivery for optimal efficiency of gene expression; 2. coupling the synthesis and release of the transgene insulin to serum glucose concentrations, especially with reference to the current promoters controlling at transcriptional level the ectopic insulin expression in autologous hepatocytes; 3. beta-cell replacement strategies: engineering of beta-cells, especially those derived from pluripotent stem cells, non beta-cells, and on a new comer, the K cells. Recent advances in the use of stem cells for potential application in diabetes gene therapy are also discussed.
Persistent Identifierhttp://hdl.handle.net/10722/76947
ISSN
2015 Impact Factor: 2.738
2015 SCImago Journal Rankings: 1.095

 

DC FieldValueLanguage
dc.contributor.authorXu, Ren_HK
dc.contributor.authorLi, Hen_HK
dc.contributor.authorTse, LYen_HK
dc.contributor.authorKung, HFen_HK
dc.contributor.authorLu, Hen_HK
dc.contributor.authorLam, KSen_HK
dc.date.accessioned2010-09-06T07:26:38Z-
dc.date.available2010-09-06T07:26:38Z-
dc.date.issued2003en_HK
dc.identifier.citationCurrent Gene Therapy, 2003, v. 3 n. 1, p. 65-82en_HK
dc.identifier.issn1566-5232en_HK
dc.identifier.urihttp://hdl.handle.net/10722/76947-
dc.description.abstractGene therapy, developing rapidly as a result of advances in molecular biology and the Human Genome Project, is now highlighted as a most hopeful technology of the 21st century. The major goal of gene therapy in diabetes mellitus (DM) is to maintain euglycemia in face of wide variations in dietary intake. Although some obstacles remain to be overcome, the risk-benefit ratio of gene therapy in DM is better than that of lifelong injections of insulin, and islet transplantation, which faces the problems of donor shortage and rejection. This review focuses on the recent advances in gene therapy of insulin-requiring diabetes, with particular emphasis on 1. the gene delivery systems by viral vectors, since most gene therapy approaches for DM involve the use of viral vectors, paying special attention to current efforts to overcome the disadvantages of adenovirus, adenovirus-associated virus and retrovirus vectors and targeting gene delivery for optimal efficiency of gene expression; 2. coupling the synthesis and release of the transgene insulin to serum glucose concentrations, especially with reference to the current promoters controlling at transcriptional level the ectopic insulin expression in autologous hepatocytes; 3. beta-cell replacement strategies: engineering of beta-cells, especially those derived from pluripotent stem cells, non beta-cells, and on a new comer, the K cells. Recent advances in the use of stem cells for potential application in diabetes gene therapy are also discussed.en_HK
dc.languageengen_HK
dc.publisherBentham Science Publishers Ltd. The Journal's web site is located at http://www.bentham.org/cgt/index.htmen_HK
dc.relation.ispartofCurrent gene therapyen_HK
dc.subject.meshDiabetes Mellitus - genetics - therapy-
dc.subject.meshGene Therapy-
dc.subject.meshInsulin - genetics - metabolism-
dc.subject.meshPituitary Gland - cytology - metabolism-
dc.subject.meshRetroviridae-
dc.titleDiabetes gene therapy: potential and challenges.en_HK
dc.typeArticleen_HK
dc.identifier.emailLam, KS:ksllam@hku.hken_HK
dc.identifier.authorityLam, KS=rp00343en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.pmid12553537en_HK
dc.identifier.scopuseid_2-s2.0-0038128172en_HK
dc.identifier.hkuros77992en_HK
dc.identifier.volume3en_HK
dc.identifier.issue1en_HK
dc.identifier.spage65en_HK
dc.identifier.epage82en_HK
dc.publisher.placeNetherlandsen_HK
dc.identifier.scopusauthoridXu, R=7402813857en_HK
dc.identifier.scopusauthoridLi, H=36078286800en_HK
dc.identifier.scopusauthoridTse, LY=36891045500en_HK
dc.identifier.scopusauthoridKung, HF=7402514190en_HK
dc.identifier.scopusauthoridLu, H=7404843265en_HK
dc.identifier.scopusauthoridLam, KS=8082870600en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats